IMDNA develops integrated molecular and immunoassay research solutions for investigating transplantation-associated immune responses, allorecognition, immune activation, immune tolerance, cytotoxic effector programs, inflammatory signaling, tissue injury, B-cell biology, and fibrotic remodeling.
Research programs can combine RT-qPCR/qPCR for targeted gene-expression or nucleic-acid measurements, ELISA for focused quantitative protein biomarker studies, and multiplex bead-based immunoassays for simultaneous measurement of multiple soluble proteins. The technology is selected according to the biological question and analyte—not treated as interchangeable.
The platform supports hypothesis-driven research across allogeneic hematopoietic cell transplantation (allo-HCT), acute and chronic graft-versus-host disease (GVHD), and broader transplantation immunology. Configurations can be tailored to pathways, analytes, specimen types, longitudinal time points, and study objectives.
Investigate antigen presentation, donor–recipient alloreactivity, T-cell activation, and immune-cell recruitment.
Profile inflammatory, cytotoxic, regulatory, B-cell, tissue-injury, and fibrosis-associated molecular programs.
Study regulatory T-cell pathways, suppressive networks, immune homeostasis, and tolerance-associated responses.
Evaluate focused sets of transplantation-related transcripts in streamlined molecular research workflows.
Support longitudinal profiling, candidate biomarker studies, experimental-treatment research, and assay development.
Transplantation immunology includes two related but distinct biological settings. In solid-organ transplantation, the recipient immune system recognizes donor alloantigens and can drive T-cell-mediated or antibody-mediated graft injury. In allogeneic hematopoietic cell transplantation, donor-derived immune cells can recognize recipient tissues and initiate GVHD. Both settings involve allorecognition, antigen presentation, lymphocyte activation, cytokine signaling, immune regulation, and tissue injury, but the direction of the immune attack and the relevant clinical biology are not interchangeable.
Recipient T cells can recognize donor antigens through direct, indirect, and semi-direct pathways. T-cell effector responses, B-cell activation, donor-specific antibodies, complement, endothelial injury, and chronic remodeling are central research themes in graft rejection.
GVHD is driven by donor-derived immune responses against recipient tissues after allo-HCT. Conditioning-associated tissue injury, antigen-presenting cells, donor T-cell activation, inflammatory cytokines, cytotoxic effector pathways, and target-organ damage are key components of acute GVHD biology.
Regulatory T cells and other regulatory mechanisms can restrain excessive alloreactivity. Research may examine FOXP3-associated programs, inhibitory pathways, IL-10/TGF-β-related networks, and the balance between effector and regulatory immune responses.
Chronic GVHD is biologically complex and may involve overlapping phases of tissue injury and innate activation, loss of immune tolerance with aberrant T- and B-cell responses, and later fibro-inflammatory remodeling.
A commonly used biological model of acute GVHD describes an interacting sequence of conditioning-associated tissue injury and inflammation, activation of antigen-presenting cells and donor T cells, followed by cytokine- and cytotoxicity-mediated target-tissue injury. These phases overlap rather than behaving as rigid clinical stages.
Pre-transplant conditioning and tissue damage can release inflammatory signals that activate innate immune pathways and antigen-presenting cells.
Donor T cells encounter recipient alloantigens, expand, differentiate, and acquire effector programs that shape GVHD severity and tissue targeting.
Activated immune cells and inflammatory mediators can damage target tissues through cytotoxic pathways and amplified inflammatory signaling.
Contemporary models of chronic GVHD describe overlapping biological phases rather than a single pathway. Early inflammation and tissue injury can evolve into impaired central and peripheral tolerance, aberrant T- and B-cell responses, and fibro-inflammatory tissue remodeling.
Study innate activation, tissue injury, IFN-associated chemokine responses, inflammatory cytokines, and epithelial-barrier stress.
Investigate Th1, Th2, Th17, T follicular helper, cytotoxic, and regulatory T-cell-associated transcriptional programs.
Explore B-cell activation, survival, germinal-center-associated responses, BAFF-related biology, and loss of B-cell tolerance.
Profile IFN-inducible and trafficking-related chemokines such as CXCL9/CXCL10-associated pathways in appropriate research contexts.
Study regulatory T-cell, regulatory B-cell, IL-10/TGF-β-related, and inhibitory pathways involved in immune homeostasis.
Investigate macrophage-associated signaling, TGF-β, extracellular-matrix regulation, collagen programs, matrix metalloproteinases, and tissue fibrosis.
Research innate effector and tissue-remodeling programs associated with chronic inflammatory and fibrotic manifestations.
Explore tissue-specific molecular responses in skin, gastrointestinal tract, oral mucosa, lung, ocular tissues, or other organs where scientifically appropriate.
Compare repair-associated, epithelial-stress, inflammatory, and remodeling signatures across longitudinal or treatment-response studies.
GVHD is biologically heterogeneous across organs. Molecular signals associated with skin, gastrointestinal, hepatic, pulmonary, oral, or ocular involvement should be interpreted in the context of tissue source, sampling time, treatment, infection, and other transplant-related complications.
Investigate epithelial injury, inflammatory signaling, barrier disruption, innate responses, repair biology, and immune-cell trafficking in GI-associated GVHD.
Study keratinocyte injury, inflammatory-cell recruitment, cytokine responses, tissue-specific stress pathways, and fibrotic remodeling.
Evaluate systemic immune activation, T-cell effector programs, inflammatory cytokines, chemokines, macrophage-associated pathways, and endothelial stress.
Explore fibrosis, extracellular-matrix remodeling, TGF-β-related pathways, macrophage biology, and persistent tissue injury in chronic GVHD models.
These examples are pathway-oriented research targets, not a fixed diagnostic panel. Selection should be based on specimen type, transplant setting, biological hypothesis, prior evidence, and assay validation. Protein biomarkers such as soluble ST2, REG3α, elafin, and BAFF are analytically distinct from RNA measurements and should not be treated as interchangeable with transcript abundance.
Targeted qPCR and RT-qPCR are most useful when the biological question, comparator group, sample source, transplant type, time point, treatment status, and normalization plan are defined before analysis.
| Research Question | Potential Molecular Focus | Critical Interpretation Context |
|---|---|---|
| Is alloreactive immune activation increasing? | T-cell activation, IFN/Th1 pathways, cytotoxicity, chemokines, inflammatory signaling | Cell composition, infection, conditioning, immunosuppression, post-transplant timing |
| Are regulatory/tolerance programs changing? | FOXP3, CTLA4, IL10, TGFB1 and other study-specific regulatory modules | Transcript levels do not directly quantify Treg frequency or suppressive function |
| Is tissue-injury biology present? | Organ-relevant epithelial, inflammatory, barrier, repair, or fibrosis-associated transcripts | Biopsy/tissue source, infection, drug toxicity, conditioning injury and other non-GVHD causes |
| Does experimental therapy alter immune pathways? | Predefined pathway modules measured before and after treatment or across dose/time groups | Baseline differences, concomitant therapy, biological replication and longitudinal design |
| Can candidate biomarker signatures be refined? | Genes selected from mechanistic literature, discovery datasets, or previous cohorts | Independent validation is required before generalizing a signature to new cohorts or clinical settings |
Several important GVHD biomarkers are circulating proteins and should be measured with validated protein-assay approaches when the research question concerns circulating protein concentration. The best-established acute GVHD example is the MAGIC framework, which uses serum concentrations of ST2 and REG3α. Elafin has been studied as a skin-associated GVHD protein biomarker, while CXCL9, CXCL10, BAFF, MMP3 and other soluble candidates have been investigated in chronic GVHD research.
GVHD diagnosis and clinical grading are not established by a generic RT-qPCR gene panel. Clinical evaluation, organ assessment, pathology when indicated, transplant context, and validated laboratory methods remain distinct from exploratory or translational molecular research.
For this reason: IMDNA positions these assays for research into mechanisms, signatures, longitudinal changes, and candidate biomarkers—not as replacements for established GVHD diagnostic or prognostic systems.
A strong transplantation biomarker program should match each biological question to the analytical layer that measures it most directly. IMDNA can combine nucleic-acid and protein technologies within one research strategy while maintaining separate validation, calibration, quality-control, and interpretation requirements for each platform.
Best suited for: targeted gene-expression profiling, pathway signatures, selected DNA targets, and longitudinal molecular studies using focused gene sets.
Development principle: follow MIQE 2.0 concepts for sample handling, assay specificity, amplification efficiency, controls, normalization, analytical range, data analysis, and transparent reporting.
Best suited for: focused quantitative measurement of an individual soluble protein when a well-characterized antibody pair and appropriate matrix-specific assay are available.
Development principle: establish calibration range, lower and upper quantification limits, precision, dilutional parallelism, recovery, matrix effects, specificity, stability, and lot-to-lot performance as appropriate to the intended research use.
Best suited for: simultaneous measurement of multiple cytokines, chemokines, growth factors, and other soluble proteins when sample volume is limited or network-level protein profiling is desired.
Development principle: each analyte must be evaluated in the multiplex context. Matrix effects, cross-reactivity, dynamic-range differences, bead recovery, standard-curve behavior, inter-run precision, operator technique, protocol adherence, and batch effects require active quality control.
The most defensible research workflow does not force every candidate biomarker onto one technology. Instead, assay development proceeds from biological hypothesis to platform selection, analytical qualification, and independent biological validation.
| Development Stage | Recommended Approach | Scientific Rationale |
|---|---|---|
| 1. Define intended research use | Specify transplant setting, biological question, analyte type, specimen, time point, comparator, and endpoint. | Prevents post-hoc biomarker selection and determines whether RNA, single-protein, multiplex-protein, or combined measurement is appropriate. |
| 2. Select biomarkers mechanistically | Use high-quality literature, pathway biology, discovery data, and study-specific hypotheses. | Pathway-informed selection is more defensible than assembling unrelated markers solely because they are measurable. |
| 3. Match analyte to technology | RT-qPCR for transcripts; ELISA for focused protein quantification; bead-based multiplex for multianalyte soluble-protein profiling. | RNA and protein measurements answer different analytical questions and cannot be assumed to substitute for one another. |
| 4. Optimize the analytical method | Establish assay-specific performance characteristics before interpreting biological differences. | Reduces the risk that apparent biological changes reflect poor efficiency, matrix interference, saturation, cross-reactivity, or batch effects. |
| 5. Qualify controls & normalization | Use technology-appropriate negative, positive, process, calibration, reference, and QC materials. | Controls must evaluate the actual failure modes of the platform and specimen matrix. |
| 6. Conduct biological verification | Test predefined contrasts in appropriately characterized samples and use longitudinal designs where scientifically relevant. | Transplant biomarkers are strongly influenced by timing, immunosuppression, infection, organ injury, and changing cell composition. |
| 7. Confirm important findings orthogonally | Where useful, compare RNA with protein, or multiplex protein findings with a focused single-analyte method. | Orthogonal confirmation helps distinguish platform-specific artifacts from reproducible biological signals. |
| 8. Validate in an independent cohort | Predefine thresholds or models and test performance outside the discovery dataset. | Independent validation is essential before proposing a biomarker signature as broadly generalizable. |
A rigorous transplantation/GVHD RT-qPCR project connects assay design to transplant setting, sampling strategy, biological controls, and mechanistic interpretation.
Rigorous transplantation biomarker research requires technology-specific analytical controls. RT-qPCR/qPCR should follow established nucleic-acid quantification principles; ELISA requires matrix-appropriate quantitative immunoassay characterization; and multiplex bead-based assays require analyte-level verification, standardized procedures, proficiency monitoring, and control of batch and operator effects.
Document transplant type, donor relationship, conditioning, graft source, prophylaxis, immunosuppression, time after transplant, infection status, and treatment exposure where relevant.
Whole blood, PBMCs, sorted cells and tissues answer different questions. Changes in leukocyte composition can alter bulk RNA signatures independently of per-cell transcriptional regulation.
Evaluate specificity, amplification efficiency, analytical range, precision, and multiplex compatibility for each intended specimen and workflow.
Include no-template, reverse-transcription, process and positive controls as appropriate to the experiment and research workflow.
Reference genes should be assessed for stability in the chosen post-transplant specimen and experimental contrast rather than assumed to be invariant.
Candidate signatures should be tested in independent cohorts before conclusions are generalized beyond the dataset in which they were developed.
Transplantation research rarely fits a universal panel. IMDNA can develop integrated research solutions using RT-qPCR/qPCR, ELISA, multiplex bead-based immunoassays, or a scientifically justified combination of these technologies around investigator-selected pathways, transplant settings, specimen types, longitudinal time points, and study objectives.
Whether your work focuses on allorecognition, graft rejection, acute GVHD, chronic GVHD, T-cell activation, cytotoxic responses, immune tolerance, B-cell biology, tissue injury, inflammatory signaling, fibrosis, biomarker discovery, or treatment-response research, IMDNA can help develop a focused molecular research approach around your biological question.